{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:14:00Z","timestamp":1774466040021,"version":"3.50.1"},"reference-count":156,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/17425255.2024.2335310","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T08:57:00Z","timestamp":1711443420000},"page":"249-262","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients"],"prefix":"10.1080","volume":"20","author":[{"given":"Justin M.","family":"Eichinger","sequence":"first","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1957-6622","authenticated-orcid":false,"given":"Divya M.","family":"Shan","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Greenzaid","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Anakwenze","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences &amp; Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Dermatology, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3"},{"key":"e_1_3_4_5_1","first-page":"1","article-title":"Psoriasis: overview and diagnosis","author":"Kimmel GW","year":"2018","unstructured":"Kimmel GW, Lebwohl M. Psoriasis: overview and diagnosis. Evid-Based Psoriasis. 2018;1\u201316.","journal-title":"Evid-Based Psoriasis"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12058"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15885"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0139"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12184"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.00998.x"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2012.04440.x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04967.x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455840"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12182"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417733414"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243040-00010"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(95)00179-4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.01.003"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.1.642"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-022-03716-8"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01637.x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.120721"},{"key":"e_1_3_4_23_1","unstructured":"PubChem. Acitretin [Internet]. [cited 2024 Jan 25]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5284513"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903393732"},{"key":"e_1_3_4_25_1","first-page":"873","article-title":"Acitretin for the treatment of psoriasis: an assessment of national trends","volume":"10","author":"Ghasri P","year":"2011","unstructured":"Ghasri P, Yentzer BA, Dabade TS, et al. Acitretin for the treatment of psoriasis: an assessment of national trends. J Drugs Dermatol JDD. 2011;10:873\u2013877.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116347"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670280066012"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.696597"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70253-X"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1000"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0137-5"},{"key":"e_1_3_4_32_1","unstructured":"Drugs and Lactation database (LactMed\u00ae). National Institute of Child Health and Human Development. 2006. [cited 2023 Dec 24]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.98558"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar419"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb07655.x"},{"key":"e_1_3_4_37_1","first-page":"23","article-title":"Neutrophil and monocyte chemotaxis in methotrexate-treated psoriasis patients","volume":"120","author":"Ternowitz T","year":"1985","unstructured":"Ternowitz T, Herlin T. Neutrophil and monocyte chemotaxis in methotrexate-treated psoriasis patients. Acta Derm Venereol Suppl (Stockh). 1985;120:23\u201326.","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)00803-X"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12612745"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2676"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1971.04000210010003"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342020-00003"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350603"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S154745"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330112"},{"key":"e_1_3_4_46_1","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt JW","year":"1993","unstructured":"Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845\u20131849.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13051"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15102"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15656"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(98)80049-8"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2340\/0001555566515519"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1985.tb02548.x"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04158.x"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.t01-1-00790.x"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.05.014"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.906"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00556900"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70199-C"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153740"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10615.x"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.017"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1913"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345060-00007"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03992.x"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.112400"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80219-8"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500423914"},{"key":"e_1_3_4_71_1","first-page":"293","article-title":"Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review","volume":"15","author":"Soleymani T","year":"2016","unstructured":"Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol. 2016;15:293\u2013301.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_72_1","first-page":"S63","article-title":"Continuous versus intermittent therapy for moderate-to-severe psoriasis","volume":"31","author":"Ramirez-Fort MK","year":"2013","unstructured":"Ramirez-Fort MK, Levin AA, Au S, et al. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31:S63\u201370.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02226.x"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00390.x"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/906349"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_4_77_1","first-page":"835","article-title":"Mechanisms underlying the clinical effects of apremilast for psoriasis","volume":"17","author":"Pincelli C","year":"2018","unstructured":"Pincelli C, Schafer PH, French LE, et al. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17:835\u2013840.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15596"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.09.003"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.019"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.604745"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38802"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12265"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.012"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2018.72.410-413"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2022.33.40-43"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071094"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.5948"},{"key":"e_1_3_4_94_1","unstructured":"Pfizer. XeljanzTM (tofacitinib) tablets for oral use: US prescribing information. 2012. Available from: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959."},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.02.003"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9080-2"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.71"},{"key":"e_1_3_4_99_1","unstructured":"US Food and Drug Administration. Xeljanz\u00ae highlights of prescribing information. 2018 cited 2024 Jan 10."},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.171"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203516"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519847414"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.053"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00010-2"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13808"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1930781100"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.07.001"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.619502"},{"key":"e_1_3_4_123_1","unstructured":"Gillooly K Zhang Y Yang X et al. BMS-986165 is a highly potent and selective Allosteric Inhibitor of Tyk2 blocks IL-12 IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease [internet]. ACR Meet. Abstr. [cited 2024 Jan 27]. Available from: https:\/\/acrabstracts.org\/abstract\/bms-986165-is-a-highly-potent-and-selective-allosteric-inhibitor-of-tyk2-blocks-il-12-il-23-and-type-i-interferon-signaling-and-provides-for-robust-efficacy-in-preclinical-models-of-systemic-lupus-e\/"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-020-00326-x"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_4_126_1","unstructured":"Bristol Myers Squibb. SOTYKTUTM (deucravacitinib) tablets for oral use: US prescribing information. 2022. cited 10 Jan 2024. https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf."},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01034-7"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091311"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.23"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2709266"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00585-1"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-018-0345-9"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00603-4"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13100"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0098"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.631"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_282_21"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16083"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16705"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12981"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.14915"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000401"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00559-1"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4172"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1017323"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.32522"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06174.x"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12039"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S188286"},{"key":"e_1_3_4_157_1","unstructured":"Tikhonova I Yang H Salmon A et al. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis [internet]. University of Exeter. 2019 [cited 2024 Jan 25]. Available from: https:\/\/www.nice.org.uk\/guidance\/DG36"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002216"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1832649"},{"key":"e_1_3_4_160_1","first-page":"302","article-title":"Can maintenance cyclosporine be used in psoriasis without decreasing renal function","volume":"11","author":"Silverman AK","year":"1992","unstructured":"Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function. Semin Dermatol. 1992;11:302\u2013312.","journal-title":"Semin Dermatol"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2335310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:27:13Z","timestamp":1727242033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2335310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":156,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/17425255.2024.2335310"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2335310","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}